Merck Seeks Early Gardasil Male Recommendation, But FDA, CDC Are Wary
Executive Summary
Merck's presentation of data on the use of Gardasil in males at FDA's recent Vaccines & Related Biological Products Advisory Committee meeting suggests the firm is positioning the product for a broader recommendation from the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices
You may also be interested in...
Cervarix, Gardasil Set For FDA Advisory Committee Review
GlaxoSmithKline knew it was in for scrutiny of its novel AS04 adjuvant, but review of Merck's application to make Gardasil gender-neutral could offer backdoor to re-examine the HPV vaccine's safety record.
Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says
Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12
Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says
Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12